Fang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fang Hu has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Feng Zhang
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011, China
10 shared publicationsHuiying Wang
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University Changsha Hunan China
10 shared publicationsDan Wu
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011, China
8 shared publicationsLijun Xie
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011, China
8 shared publicationsWei Chen
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011, China
8 shared publicationsZhinan Chen
National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University Changsha Hunan China
8 shared publications
Latest Publications
- 9 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 8913-8924
Efficacy and Safety of Anti‐Obesity Medications for Weight Loss Maintenance in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Aims: This systematic review and meta‐analysis aimed to evaluate the efficacy and safety of anti‐obesity medications (AOMs) for long‐term weight maintenance following initial weight loss in adults with overweight or obesity. Methods: We searched PubMed, Embase, Web of Science and the Cochrane Library from inception to 31 October 2025. Eligible studies were randomised controlled trials (RCTs) comparing AOMs with placebo during the weight‐maintenance phase in adults with overweight or obesity after initial weight loss achieved through lifestyle, dietary, surgical or pharmacological interventions. Outcomes included anthropometric indices, cardiometabolic measures, safety endpoints, quality of life and neuropsychiatric adverse events. Weighted mean differences (WMDs) and odds ratios (ORs), each with 95% confidence intervals (CIs), were pooled for continuous and categorical outcomes, respectively, using fixed‐effect or random‐effects models as appropriate. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. The protocol was registered with PROSPERO (CRD420261293040). Results: A total of 12 RCTs comprising 4915 participants met the inclusion criteria. Compared with placebo, AOM therapy during the weight‐maintenance phase was associated with prevention of weight regain and additional improvements in anthropometric and cardiometabolic outcomes. AOMs led to further reductions in body weight (BW, WMD: −8.68 kg, 95% CI: −13.25 to −4.11), waist circumference (WC, WMD: −7.16 cm, 95% CI: −10.34 to −3.98) and body mass index (BMI, WMD: −3.58 kg/m 2 , 95% CI: −5.69 to −1.46). Additional benefits were observed for triglycerides, total cholesterol, low‐density lipoprotein cholesterol, systolic blood pressure and diastolic blood pressure. Gastrointestinal adverse events were more common with AOMs, whereas serious adverse events were not significantly increased. Neuropsychiatric adverse events were generally comparable between groups, and available quality‐of‐life measures favoured AOM treatment. Conclusions: AOM therapy during the weight‐maintenance phase can help prevent weight regain, provide further reductions in body weight and improve cardiometabolic risk factors in adults with overweight or obesity. Gastrointestinal adverse events were more common with AOMs, whereas serious adverse events were not significantly increased. Further long‐term trials are needed to clarify optimal treatment strategies and safety.
- 9 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 8913-8924
Efficacy and Safety of Anti‐Obesity Medications for Weight Loss Maintenance in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Aims: This systematic review and meta‐analysis aimed to evaluate the efficacy and safety of anti‐obesity medications (AOMs) for long‐term weight maintenance following initial weight loss in adults with overweight or obesity. Methods: We searched PubMed, Embase, Web of Science and the Cochrane Library from inception to 31 October 2025. Eligible studies were randomised controlled trials (RCTs) comparing AOMs with placebo during the weight‐maintenance phase in adults with overweight or obesity after initial weight loss achieved through lifestyle, dietary, surgical or pharmacological interventions. Outcomes included anthropometric indices, cardiometabolic measures, safety endpoints, quality of life and neuropsychiatric adverse events. Weighted mean differences (WMDs) and odds ratios (ORs), each with 95% confidence intervals (CIs), were pooled for continuous and categorical outcomes, respectively, using fixed‐effect or random‐effects models as appropriate. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. The protocol was registered with PROSPERO (CRD420261293040). Results: A total of 12 RCTs comprising 4915 participants met the inclusion criteria. Compared with placebo, AOM therapy during the weight‐maintenance phase was associated with prevention of weight regain and additional improvements in anthropometric and cardiometabolic outcomes. AOMs led to further reductions in body weight (BW, WMD: −8.68 kg, 95% CI: −13.25 to −4.11), waist circumference (WC, WMD: −7.16 cm, 95% CI: −10.34 to −3.98) and body mass index (BMI, WMD: −3.58 kg/m 2 , 95% CI: −5.69 to −1.46). Additional benefits were observed for triglycerides, total cholesterol, low‐density lipoprotein cholesterol, systolic blood pressure and diastolic blood pressure. Gastrointestinal adverse events were more common with AOMs, whereas serious adverse events were not significantly increased. Neuropsychiatric adverse events were generally comparable between groups, and available quality‐of‐life measures favoured AOM treatment. Conclusions: AOM therapy during the weight‐maintenance phase can help prevent weight regain, provide further reductions in body weight and improve cardiometabolic risk factors in adults with overweight or obesity. Gastrointestinal adverse events were more common with AOMs, whereas serious adverse events were not significantly increased. Further long‐term trials are needed to clarify optimal treatment strategies and safety.
- Open Access
- 16 April 2026
- Published by Elsevier in Metabolism
- Vol. 180, 156622
Hepatocyte DDIT4 aggravates MASH progression through GPX4-mediated ferroptosis
- 16 April 2026
- Published by Elsevier in Metabolism
- Vol. 180, 156622
Open AccessHepatocyte DDIT4 aggravates MASH progression through GPX4-mediated ferroptosis
- Open Access
- 12 February 2026
- Published by Elsevier in Journal of Advanced Research
- Vol. 89, 621-638
A novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity
- 12 February 2026
- Published by Elsevier in Journal of Advanced Research
- Vol. 89, 621-638
Open AccessA novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity
- Open Access
- 11 November 2025
- Published by Wiley in Advanced Science
- Vol. 12 (46) , e07451
Integrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers
Single‐cell expression quantitative trait loci data offer promising opportunities to inform immune‐related drug development in cancer. However, pleiotropy can complicate causal inference. We introduce MR‐DEG, a framework that integrates Mendelian randomization (MR) and differential expressed gene (DEG) to strengthen causal inference. Using eight conventional MR and colocalization methods, we estimated effects of 11 021 dynamic gene expression profiles during CD4+ T cell activation on the risk of six cancer types. This identified 1000 gene‐cancer pairs with putative effects ( https://www.omicsharbour.com/sc‐eqtl‐mr ). Of these 1000 pairs, 517 involved 205 unique genes that were differentially expressed in relevant cancer tissues based on single‐cell RNA‐sequencing data. Of these 517 pairs, 265 were classified as likely causal using the conventional MR methods. After applying MR‐DEG to the remaining 252 potentially pleiotropic pairs, an additional 89 were classified as likely causal. Sixty‐four and 391 of the 1000 original pairs exhibited time‐ and non‐time dependent effects on cancer risk, respectively. Integrating the 1000 gene‐cancer pairs of MR findings and clinical trial evidence, we identified 200 pairs corresponding to 33 unique genes that encode drug targets under clinical investigation. These results demonstrate how combining genetic, transcriptomic and clinical trial evidence can reduce pleiotropic bias, and prioritize immune‐related drug targets for cancer prevention.
- 11 November 2025
- Published by Wiley in Advanced Science
- Vol. 12 (46) , e07451
Open AccessIntegrating Single‐Cell Transcriptome‐Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune‐Related Drug Targets for Cancers
Single‐cell expression quantitative trait loci data offer promising opportunities to inform immune‐related drug development in cancer. However, pleiotropy can complicate causal inference. We introduce MR‐DEG, a framework that integrates Mendelian randomization (MR) and differential expressed gene (DEG) to strengthen causal inference. Using eight conventional MR and colocalization methods, we estimated effects of 11 021 dynamic gene expression profiles during CD4+ T cell activation on the risk of six cancer types. This identified 1000 gene‐cancer pairs with putative effects ( https://www.omicsharbour.com/sc‐eqtl‐mr ). Of these 1000 pairs, 517 involved 205 unique genes that were differentially expressed in relevant cancer tissues based on single‐cell RNA‐sequencing data. Of these 517 pairs, 265 were classified as likely causal using the conventional MR methods. After applying MR‐DEG to the remaining 252 potentially pleiotropic pairs, an additional 89 were classified as likely causal. Sixty‐four and 391 of the 1000 original pairs exhibited time‐ and non‐time dependent effects on cancer risk, respectively. Integrating the 1000 gene‐cancer pairs of MR findings and clinical trial evidence, we identified 200 pairs corresponding to 33 unique genes that encode drug targets under clinical investigation. These results demonstrate how combining genetic, transcriptomic and clinical trial evidence can reduce pleiotropic bias, and prioritize immune‐related drug targets for cancer prevention.
- 10 October 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (1) , 199-213
Berberine combined with stachyose protects against obesity by modulating gut microbiota and increasing leptin sensitivity
Leptin resistance is a hallmark of obesity. Recent evidence shows that gut microbiota is associated with the development and progression of leptin resistance. However, whether intervention targeting gut microbiota can improve leptin sensitivity remains to be fully established. In the current investigation, we have demonstrated that co-administration of berberine, an isoquinoline alkaloid compound, and stachyose, a prebiotic, could enhance leptin sensitivity and reduce body weight in diet-induced obesity (DIO) mice, via an effect associated with gut microbiota modulation. Notably, the combination of berberine and stachyose significantly increased the abundance of Blautia producta, altered host purine metabolism, and elevated serum and hypothalamic levels of a purine metabolite, inosine. Furthermore, direct supplementation with inosine further ameliorated inflammation and endoplasmic reticulum stress in the hypothalamus and improved leptin sensitivity in obese mice. These findings suggest that berberine combined with stachyose represents a novel leptin sensitizer for obesity, acting through the modulation of gut microbiota and subsequently alteration in host purine metabolism, particularly with the involvement of inosine.
- 10 October 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (1) , 199-213
Berberine combined with stachyose protects against obesity by modulating gut microbiota and increasing leptin sensitivity
Leptin resistance is a hallmark of obesity. Recent evidence shows that gut microbiota is associated with the development and progression of leptin resistance. However, whether intervention targeting gut microbiota can improve leptin sensitivity remains to be fully established. In the current investigation, we have demonstrated that co-administration of berberine, an isoquinoline alkaloid compound, and stachyose, a prebiotic, could enhance leptin sensitivity and reduce body weight in diet-induced obesity (DIO) mice, via an effect associated with gut microbiota modulation. Notably, the combination of berberine and stachyose significantly increased the abundance of Blautia producta, altered host purine metabolism, and elevated serum and hypothalamic levels of a purine metabolite, inosine. Furthermore, direct supplementation with inosine further ameliorated inflammation and endoplasmic reticulum stress in the hypothalamus and improved leptin sensitivity in obese mice. These findings suggest that berberine combined with stachyose represents a novel leptin sensitizer for obesity, acting through the modulation of gut microbiota and subsequently alteration in host purine metabolism, particularly with the involvement of inosine.
- 12 November 2024
- Published by Elsevier in Separation and Purification Technology
- Vol. 359, 130502
From waste to material strategy: A closed-loop regeneration process of spent LiFePO4 batteries
- 12 November 2024
- Published by Elsevier in Separation and Purification Technology
- Vol. 359, 130502
From waste to material strategy: A closed-loop regeneration process of spent LiFePO4 batteries
- Top Cited PapersOpen Access
- 2 October 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 5713-5726
Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta‐analysis of randomized controlled trials
Aim: To assess the effects of vitamin D interventions on glycaemic control in subjects with type 2 diabetes (T2D). Methods: We searched PubMed, EMBASE, Web of Science and the Cochrane Library for relevant studies. Serum 25(OH)D, fasting blood glucose (FBG), HbA1c, fasting insulin and Homeostasis Model Assessment for Insulin Resistance (HOMA‐IR) were analysed. Results: We identified 39 randomized controlled trials involving 2982 subjects. Results showed a significant decline in the vitamin D group, as shown by the FBG weighted mean difference (WMD; −0.49 [95% confidence interval {CI}: −0.69 to −0.28] mmol/L), HbA1c (WMD −0.30% [95% CI: −0.43 to −0.18]), HOMA‐IR (WMD −0.39 [95% CI −0.64 to −0.14]) and insulin (WMD −1.31 [95% CI: −2.06 to −0.56] μIU/mL). Subgroup analyses indicated that the effects of vitamin D supplementation on glycaemic control depend on the dosage and duration of supplementation, baseline 25(OH)D levels and the body mass index of patients with T2D. Conclusions: Vitamin D supplementation can significantly reduce serum FBG, HbA1c, HOMA‐IR and fasting insulin levels in T2D patients; the effects were especially prominent when vitamin D was given in a short‐term, high dosage to patients with a vitamin D deficiency, who were overweight, or had an HbA1c of 8% or higher at baseline. Our study suggests that vitamin D supplements can be recommended as complementary treatment for T2D patients.
- 2 October 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 5713-5726
Top Cited PapersOpen AccessEfficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta‐analysis of randomized controlled trials
Aim: To assess the effects of vitamin D interventions on glycaemic control in subjects with type 2 diabetes (T2D). Methods: We searched PubMed, EMBASE, Web of Science and the Cochrane Library for relevant studies. Serum 25(OH)D, fasting blood glucose (FBG), HbA1c, fasting insulin and Homeostasis Model Assessment for Insulin Resistance (HOMA‐IR) were analysed. Results: We identified 39 randomized controlled trials involving 2982 subjects. Results showed a significant decline in the vitamin D group, as shown by the FBG weighted mean difference (WMD; −0.49 [95% confidence interval {CI}: −0.69 to −0.28] mmol/L), HbA1c (WMD −0.30% [95% CI: −0.43 to −0.18]), HOMA‐IR (WMD −0.39 [95% CI −0.64 to −0.14]) and insulin (WMD −1.31 [95% CI: −2.06 to −0.56] μIU/mL). Subgroup analyses indicated that the effects of vitamin D supplementation on glycaemic control depend on the dosage and duration of supplementation, baseline 25(OH)D levels and the body mass index of patients with T2D. Conclusions: Vitamin D supplementation can significantly reduce serum FBG, HbA1c, HOMA‐IR and fasting insulin levels in T2D patients; the effects were especially prominent when vitamin D was given in a short‐term, high dosage to patients with a vitamin D deficiency, who were overweight, or had an HbA1c of 8% or higher at baseline. Our study suggests that vitamin D supplements can be recommended as complementary treatment for T2D patients.
- Open Access
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1375138
Dynamic changes of immunocyte subpopulations in thermogenic activation of adipose tissues
Objectives: The effects of cold exposure on whole-body metabolism in humans have gained increasing attention. Brown or beige adipose tissues are crucial in cold-induced thermogenesis to dissipate energy and thus have the potential to combat metabolic disorders. Despite the immune regulation of thermogenic adipose tissues, the overall changes in vital immune cells during distinct cold periods remain elusive. This study aimed to discuss the overall changes in immune cells under different cold exposure periods and to screen several potential immune cell subpopulations on thermogenic regulation.Methods: Cibersort and mMCP-counter algorithms were employed to analyze immune infiltration in two (brown and beige) thermogenic adipose tissues under distinct cold periods. Changes in some crucial immune cell populations were validated by reanalyzing the single-cell sequencing dataset (GSE207706). Flow cytometry, immunofluorescence, and quantitative real-time PCR assays were performed to detect the proportion or expression changes in mouse immune cells of thermogenic adipose tissues under cold challenge.Results: The proportion of monocytes, naïve, and memory T cells increased, while the proportion of NK cells decreased under cold exposure in brown adipose tissues.Conclusion: Our study revealed dynamic changes in immune cell profiles in thermogenic adipose tissues and identified several novel immune cell subpopulations, which may contribute to thermogenic activation of adipose tissues under cold exposure.
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1375138
Open AccessDynamic changes of immunocyte subpopulations in thermogenic activation of adipose tissues
Objectives: The effects of cold exposure on whole-body metabolism in humans have gained increasing attention. Brown or beige adipose tissues are crucial in cold-induced thermogenesis to dissipate energy and thus have the potential to combat metabolic disorders. Despite the immune regulation of thermogenic adipose tissues, the overall changes in vital immune cells during distinct cold periods remain elusive. This study aimed to discuss the overall changes in immune cells under different cold exposure periods and to screen several potential immune cell subpopulations on thermogenic regulation.Methods: Cibersort and mMCP-counter algorithms were employed to analyze immune infiltration in two (brown and beige) thermogenic adipose tissues under distinct cold periods. Changes in some crucial immune cell populations were validated by reanalyzing the single-cell sequencing dataset (GSE207706). Flow cytometry, immunofluorescence, and quantitative real-time PCR assays were performed to detect the proportion or expression changes in mouse immune cells of thermogenic adipose tissues under cold challenge.Results: The proportion of monocytes, naïve, and memory T cells increased, while the proportion of NK cells decreased under cold exposure in brown adipose tissues.Conclusion: Our study revealed dynamic changes in immune cell profiles in thermogenic adipose tissues and identified several novel immune cell subpopulations, which may contribute to thermogenic activation of adipose tissues under cold exposure.
- Open Access
- 29 February 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 222, 116104
The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases
- 29 February 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 222, 116104
Open AccessThe role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): Connections and interactions in liver diseases
- Open Access
- 16 January 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1294362
Comparative efficacy of exercise training modes on systemic metabolic health in adults with overweight and obesity: a network meta-analysis of randomized controlled trials
Objective: This network meta-analysis (NMA) was conducted to compare and rank the effects of training interventions including aerobic exercise (AE), resistance training (RT), combined aerobic and resistance training (CT), and high-intensity interval training (HIIT) on vital metabolic indicators in adults with overweight and obesity.Methods: PubMed, Cochrane, Embase, and Web of Science were searched from 1990 to February 2023. Articles were included if they described randomized controlled trials (RCTs) examining the effects of exercise training on anthropometry parameters, lipid profiles, glucose metabolism, blood pressure, and cardiorespiratory fitness in adults with overweight and obesity. Weighted mean difference with 95% CI was calculated.Results: A total of 28 studies with 1,620 patients were included. Results revealed that AE exerts best effects on weight loss (−2.35 [−4.05, −0.64]) and body mass index (−0.9 [−1.38, −0.42]), while HIIT is the most effective in reducing waist circumference (−5.93 [10.71, −1.15]), percentage body fat (−3.93 [−5.73, −2.12]), serum triglycerides (−20.55 [−37.20, −3.91]), and fasting blood glucose (−14.31 [−22.47, −6.16]) and improving VO2 max (7.41 [4.37, 10.45]). However, no significant benefit was observed in terms of total cholesterol and blood pressure.Conclusions: AE is the optimal exercise type for reducing body weight and BMI, while HIIT exerts the most beneficial effects on improving body composition, cardiorespiratory fitness, and metabolic abnormalities in adults with overweight and obesity.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023444322, identifier CRD42023444322.
- 16 January 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1294362
Open AccessComparative efficacy of exercise training modes on systemic metabolic health in adults with overweight and obesity: a network meta-analysis of randomized controlled trials
Objective: This network meta-analysis (NMA) was conducted to compare and rank the effects of training interventions including aerobic exercise (AE), resistance training (RT), combined aerobic and resistance training (CT), and high-intensity interval training (HIIT) on vital metabolic indicators in adults with overweight and obesity.Methods: PubMed, Cochrane, Embase, and Web of Science were searched from 1990 to February 2023. Articles were included if they described randomized controlled trials (RCTs) examining the effects of exercise training on anthropometry parameters, lipid profiles, glucose metabolism, blood pressure, and cardiorespiratory fitness in adults with overweight and obesity. Weighted mean difference with 95% CI was calculated.Results: A total of 28 studies with 1,620 patients were included. Results revealed that AE exerts best effects on weight loss (−2.35 [−4.05, −0.64]) and body mass index (−0.9 [−1.38, −0.42]), while HIIT is the most effective in reducing waist circumference (−5.93 [10.71, −1.15]), percentage body fat (−3.93 [−5.73, −2.12]), serum triglycerides (−20.55 [−37.20, −3.91]), and fasting blood glucose (−14.31 [−22.47, −6.16]) and improving VO2 max (7.41 [4.37, 10.45]). However, no significant benefit was observed in terms of total cholesterol and blood pressure.Conclusions: AE is the optimal exercise type for reducing body weight and BMI, while HIIT exerts the most beneficial effects on improving body composition, cardiorespiratory fitness, and metabolic abnormalities in adults with overweight and obesity.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023444322, identifier CRD42023444322.